Therapeutic potential of interleukin‑15 in cancer (Review)
- Authors:
- Gheorghița Isvoranu
- Mihaela Surcel
- Adriana Narcisa Munteanu
- Ovidiu Gabriel Bratu
- Florentina Ionita‑Radu
- Monica Teodora Neagu
- Marioara Chiritoiu‑Butnaru
-
Affiliations: Department of Animal Husbandry, ‘Victor Babes’ National Institute of Pathology, 050096 Bucharest, Romania, Department of Immunology, ‘Victor Babes’ National Institute of Pathology, 050096 Bucharest, Romania, Clinical Department III, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Gastroenterology, ‘Dr. Carol Davila’ University Emergency Central Military Hospital, 010825 Bucharest, Romania, Department of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy (IBAR), 060031 Bucharest, Romania - Published online on: April 24, 2021 https://doi.org/10.3892/etm.2021.10107
- Article Number: 675
-
Copyright: © Isvoranu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Isvoranu G: The Memory Activation of NK Cells: New Methods in Cancer Immunotherapy. In: Immunotherapy-Myths, Reality, Ideas, Future. InTech, Rijeka, pp201-219, 2017. | |
McCune JS: Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther. 103:540–544. 2018.PubMed/NCBI View Article : Google Scholar | |
Palmer AC and Sorger PK: Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 171:1678–1691. 2017.PubMed/NCBI View Article : Google Scholar | |
Marcu D, Spinu D, Mischianu D, Sorcea B, Oprea I and Bratu O: Oncological follow-up after radical prostatectomy. Rom J Mil Med. 120:39–42. 2017. | |
Popescu R, Bratu O, Spinu D, Marcu D, Farcas C, Dinu M and Mischianu D: Neuroendocrine differentiation in prostate cancer-a review. Rom J Mil Med. 118:16–19. 2015. | |
Tormoen GW, Crittenden MR and Gough MJ: Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiant Oncol. 3:520–526. 2018.PubMed/NCBI View Article : Google Scholar | |
Zhang Y and Zhang Z: The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 17:807–821. 2020.PubMed/NCBI View Article : Google Scholar | |
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E and Melero I: Cytokines in clinical cancer immunotherapy. Br J Cancer. 120:6–15. 2019.PubMed/NCBI View Article : Google Scholar | |
Lee S and Margolin K: Cytokines in cancer immunotherapy. Cancers (Basel). 3:3856–3893. 2011.PubMed/NCBI View Article : Google Scholar | |
Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet. 356:795–1799. 2000.PubMed/NCBI View Article : Google Scholar | |
Thommen DS and Schumacher TN: T cell dysfunction in cancer. Cancer Cell. 33:547–562. 2018.PubMed/NCBI View Article : Google Scholar | |
Isvoranu G, Surcel M, Huică RI, Munteanu AN, Pîrvu IR, Ciotaru D, Constantin C, Bratu O, Neagu M and Ursaciuc C: Natural killer cell monitoring in cutaneous melanoma-new dynamic biomarker. Oncol Lett. 17:4197–206. 2019.PubMed/NCBI View Article : Google Scholar | |
Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ and Rubinstein MP: IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 38:45–68. 2018.PubMed/NCBI View Article : Google Scholar | |
Farhood B, Najafi M and Mortezaee K: CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physio. 234:8509–8521. 2019.PubMed/NCBI View Article : Google Scholar | |
Floros T and Tarhini AA: Anticancer Cytokines: Biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 42:539–548. 2015.PubMed/NCBI View Article : Google Scholar | |
Chulpanova DS, Kitaeva KV, Green AR, Rizvanov AA and Solovyeva VV: Molecular aspects and future perspectives of cytokine-based anti-cancer immunotherapy. Front Cell Dev Biol. 8(402)2020.PubMed/NCBI View Article : Google Scholar | |
Cheever MA: Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 222:357–368. 2008.PubMed/NCBI View Article : Google Scholar | |
Waldmann TA, Miljkovic MD and Conlon KC: Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. J Exp Med. 217(e20191062)2020.PubMed/NCBI View Article : Google Scholar | |
Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E and Waldmann TA: A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. 91:4935–4939. 1994.PubMed/NCBI View Article : Google Scholar | |
Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al: Cloning of a T Cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 264:965–968. 1994.PubMed/NCBI View Article : Google Scholar | |
Steel JC, Waldmann TA and Morris JC: Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 33:35–41. 2012.PubMed/NCBI View Article : Google Scholar | |
Budagian V, Bulanova E, Paus R and Bulfone-Paus S: IL-15/IL-15 receptor biology: A guided tour through an expanding universe. Cytokine Growth Factor Rev. 17:259–280. 2006.PubMed/NCBI View Article : Google Scholar | |
Mishra A, Sullivan L and Caligiuri MA: Molecular pathways: Interleukin-15 signaling in health and in cancer. Clin Cancer Res. 20:2044–2050. 2014.PubMed/NCBI View Article : Google Scholar | |
Waldmann TA: The shared and contrasting roles of interleukin-2 (IL-2) and IL-15 in the life and death of normal and neoplastic lymphocytes: Implications for cancer therapy. Cancer Immunol Res. 3:219–227. 2015.PubMed/NCBI View Article : Google Scholar | |
Ahmadzadeh M and Rosenberg SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 107:2409–2414. 2006.PubMed/NCBI View Article : Google Scholar | |
Waldmann TA: Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther. 6:174–177. 2004.PubMed/NCBI View Article : Google Scholar | |
Kirman I and Nielsen OH: Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am J Gastroenterol. 91:1789–1794. 1996.PubMed/NCBI | |
Liu Z, Geboes K, Colpaert S, D'Haens GR, Rutgeerts P and Ceuppens JL: IL-15 is highly expressed in inflammatory bowel disease and regulates local t cell-dependent cytokine production. J Immunol. 164:3608–3615. 2000.PubMed/NCBI View Article : Google Scholar | |
Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, et al: Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum. 52:2686–2692. 2005.PubMed/NCBI View Article : Google Scholar | |
Iftimie G, Stanescu A, Iancu M, Stoian A, Hainarosie R, Socea B, Isvoranu G, Marcu D, Neagu TP and Diaconu CC: The importance of early arthritis in patients with rheumatoid arthritis. J Mind Med Sci. 5:176–183. 2018. | |
Kivisäkk P, Matusevicius D, He B, Söderström M, Fredrikson S and Link H: IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clin Exp Immunol. 111:193–197. 1998.PubMed/NCBI View Article : Google Scholar | |
Rentzos M, Cambouri C, Rombos A, Nikolaou C, Anagnostouli M, Tsoutsou A, Dimitrakopoulos A, Triantafyllou N and Vassilopoulos D: IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci. 241:25–29. 2006.PubMed/NCBI View Article : Google Scholar | |
Robinson TO and Schluns KS: The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. 190:159–168. 2017.PubMed/NCBI View Article : Google Scholar | |
Waldmann TA: Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 10:1689–1701. 2014.PubMed/NCBI View Article : Google Scholar | |
Zhang X, Sun S, Hwang I, Tough DF and Sprent J: Potent and selective stimulation of memory-phenotype CD8+ T Cells in vivo by IL-15. Immunity. 8:591–599. 1998.PubMed/NCBI View Article : Google Scholar | |
Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, et al: Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 117:4787–4795. 2011.PubMed/NCBI View Article : Google Scholar | |
Stoklasek TA, Schluns KS and Lefrançois L: Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 177:6072–6080. 2006.PubMed/NCBI View Article : Google Scholar | |
Isvoranu G, Marinescu B, Surcel M, Ursaciuc C and Manda G: Immunotherapy in cancer-in vivo study of the antitumor activity of the IL-15/IL-15R alfa combination in an experimental model of melanoma. Farmacia. 63:631–636. 2015. | |
Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, et al: Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 201:139–148. 2005.PubMed/NCBI View Article : Google Scholar | |
Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, et al: Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 8(357ra123)2016.PubMed/NCBI View Article : Google Scholar | |
Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV and Waldmann TA: IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci USA. 115:E10915–E10924. 2018.PubMed/NCBI View Article : Google Scholar | |
Robert H: Vonderheide: CD40 agonist antibodies in cancer Immunotherapy. Annu Rev Med. 71:47–58. 2020.PubMed/NCBI View Article : Google Scholar | |
Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ and Vonderheide RH: Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 3:399–411. 2015.PubMed/NCBI View Article : Google Scholar | |
Byrne KT and Vonderheide RH: CD40 Stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15:2719–2732. 2016.PubMed/NCBI View Article : Google Scholar | |
Li DK and Wang W: Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. Oncol Lett. 20(176)2020.PubMed/NCBI View Article : Google Scholar | |
Van Audenaerde JR, Marcq E, von Scheidt B, Davey AS, Oliver AJ, De Waele J, Quatannens D, Van Loenhout J, Pauwels P, Roeyen G, et al: Novel combination immunotherapy for pancreatic cancer: Potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Clin Transl Immunology. 9(e1165)2020.PubMed/NCBI View Article : Google Scholar | |
Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP and Waldmann TA: Augmented interleukin IL-15Rα expression by CD40 activation is critical in synergistic CD8 T-cell mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol. 188:6156–6164. 2012.PubMed/NCBI View Article : Google Scholar | |
Perez CR and De Palma M: Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 10(5408)2019.PubMed/NCBI View Article : Google Scholar | |
Palucka K and Banchereau J: Dendritic cell-based cancer therapeutic vaccines. Immunity. 39:38–48. 2013.PubMed/NCBI View Article : Google Scholar | |
Anguille S, Lion E, Van den Bergh J, Van Acker HH, Willemen Y, Smits EL, Van Tendeloo VF and Berneman ZN: Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccines Immunother. 9:1956–1961. 2013.PubMed/NCBI View Article : Google Scholar | |
Van Acker HH, Anguille S, De Reu H, Berneman ZN, Smits EL and Van Tendeloo VF: Interleukin-15-cultured dendritic cells enhance anti-tumor gamma delta T cell functions through IL-15 Secretion. Front Immunol. 9(658)2018.PubMed/NCBI View Article : Google Scholar | |
Zhu X, Marcus WD, Xu W, Hi L, Han K, Egan JO, Yovandich JL, Rhode PR and Wong HC: Novel human Interleukin15 agonists. J Immunol. 183:3598–3607. 2009.PubMed/NCBI View Article : Google Scholar | |
Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, et al: Efficacy and mechanism-of-action of a novel superagonist interleukin-15: Interleukin-15 receptor αSu/fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73:3075–3086. 2013.PubMed/NCBI View Article : Google Scholar | |
Hu Q, Ye X, Qu X, Cui D, Zang L, Xu Z, Wan H, Zhang L and Tao W: Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy. Sci Rep. 8(7675)2018.PubMed/NCBI View Article : Google Scholar | |
Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, Liu B, Zhu X, Wen J, You L, et al: Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 4:49–60. 2016.PubMed/NCBI View Article : Google Scholar | |
Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, et al: Phase I trial of ALT-803, a novel recombinant Interleukin-15 complex, in patients with advanced solid tumors. Clin Cancer Res. 24:5552–5561. 2018.PubMed/NCBI View Article : Google Scholar | |
Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, et al: First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 131:2515–2527. 2018.PubMed/NCBI View Article : Google Scholar | |
Knudson KM, James W, Hodge JW, Schlom J and Gameiro SR: Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin Biol Ther. 20:705–709. 2020.PubMed/NCBI View Article : Google Scholar | |
Waldmann TA, Dubois S, Miljkovic MD and Conlon KC: IL-15 in the combination immunotherapy of cancer. Front Immunol. 11(868)2020.PubMed/NCBI View Article : Google Scholar | |
Mortier E, Quemener A, Vusio P, Lorenzen I, Boublink Y, Grötzinger J, Plet A and Jacques Y: Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 281:1612–1619. 2006.PubMed/NCBI View Article : Google Scholar | |
Desbois M, Le Vu P, Coutzac C, Marcheteau E, Béal C, Terme M, Gey A, Morisseau S, Teppaz G, Boselli L, et al: IL-15 trans-signaling with the superagonist RLI promotes Effector/Memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists. J Immunol. 197:168–178. 2016.PubMed/NCBI View Article : Google Scholar | |
Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14:1014–1022. 2013.PubMed/NCBI View Article : Google Scholar | |
Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF and Wang D: Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 9:901–909. 2015.PubMed/NCBI View Article : Google Scholar | |
Postow MA, Callahan MK and Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol. 33:1974–1982. 2015.PubMed/NCBI View Article : Google Scholar | |
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372:2521–2532. 2015.PubMed/NCBI View Article : Google Scholar | |
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Eng J Med. 376:2415–2426. 2017.PubMed/NCBI View Article : Google Scholar | |
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Eng J Med. 376:1015–1026. 2017.PubMed/NCBI View Article : Google Scholar | |
Mathios D, Park CK, Marcus WD, Alter S, Rhode PR, Jeng EK, Wong HC, Pardoll DM and Lim M: Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer. 138:187–194. 2016.PubMed/NCBI View Article : Google Scholar | |
Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Scholm J and Hodge JW: IL-15 superagonist/IL-15RαSushi-fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget. 7:16130–16145. 2016.PubMed/NCBI View Article : Google Scholar | |
Knudson KM, Hicks KC, Alter S, Schlomand J and Gameiro SR: Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer. 7(82)2019.PubMed/NCBI View Article : Google Scholar | |
Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y and Guo ZS: Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 12(103)2013.PubMed/NCBI View Article : Google Scholar | |
Stephenson KB, Barra NG, Davies E, Ashkar AA and Lichty BD: Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 19:238–246. 2012.PubMed/NCBI View Article : Google Scholar | |
Tosic V, Thomas DL, Kranz DM, Liu J, McFadden G, Shisler JL, MacNeill AL and Roy EJ: Myxoma virus expressing a fusion protein of interleukin-15 (IL-15) and IL-15 receptor alpha has enhanced antitumor activity. PLoS One. 9(e109801)2014.PubMed/NCBI View Article : Google Scholar | |
Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, Dai E, Roy EJ, Guo ZS and Bartlett DL: Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade. Mol Ther. 26:2476–2486. 2018.PubMed/NCBI View Article : Google Scholar | |
Rosenberg SA, Yang JC, White DE and Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg. 228:307–319. 1998.PubMed/NCBI View Article : Google Scholar | |
Schwartz RN, Stover L and Dutcher JP: Managing toxicities of high-dose interleukin-2. Oncology. 16:11–20. 2002.PubMed/NCBI | |
Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC and Riddell SR: Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 114:2417–2426. 2009.PubMed/NCBI View Article : Google Scholar | |
Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus MN, Perera LP, et al: IL15 by Continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. Clin Cancer Res. 25:4945–4954. 2019.PubMed/NCBI View Article : Google Scholar | |
Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, et al: Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human Interleukin-15 in patients with cancer. J Clin Oncol. 33:74–82. 2015.PubMed/NCBI View Article : Google Scholar | |
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, et al: ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: A non-randomised, open-label, phase 1b trial. Lancet Oncol. 19:694–704. 2018.PubMed/NCBI View Article : Google Scholar | |
Huang J, Schisler J, Wong HC, Rosser CJ and Sterbis J: Intravesical ALT-803 for BCG-unresponsive bladder cancer-A Case Report. Uro Case Rep. 14:15–17. 2017.PubMed/NCBI View Article : Google Scholar | |
ImmunityBio granted FDA Breakthrough therapy designation for N-803 Il-15 superagonist in non-muscle invasive bladder cancer. News release. BioSpace. December 4, 2019. http://bit.ly/2ZgGAvM. | |
Desbois M, Béal C, Charrier M, Besse B, Meurice G, Cagnard N, Jacques Y, Béchard D, Cassard L and Chaput N: IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: Implications for antimetastatic treatment. J Immunother Cancer. 8(e000632)2020.PubMed/NCBI View Article : Google Scholar |